SEC Form 4 · accession 0001214659-19-001618
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles M Baum
Officer — President & CEO · Director
Period of report
Feb 25, 2019
Accepted (ET)
Feb 27, 2019 · 7:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 25, 2019 | M | 51,810 | $8.50 | A | 117,851 | D | |
| Common StockF2 | Feb 25, 2019 | S | 25,722 | $75.1712 | D | 92,129 | D | |
| Common StockF3 | Feb 25, 2019 | S | 18,235 | $75.7687 | D | 73,894 | D | |
| Common StockF4 | Feb 25, 2019 | S | 5,687 | $76.7545 | D | 68,207 | D | |
| Common StockF5 | Feb 25, 2019 | S | 2,066 | $77.9593 | D | 66,141 | D | |
| Common Stock | Feb 25, 2019 | S | 100 | $79.09 | D | 66,041 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common StockF6 | $8.50 | Feb 25, 2019 | M | 51,810 | D | — | Jul 16, 2020 | Common Stock | 51,810 | 51,810 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $74.43 to $75.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $75.430 to $76.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $76.435 to $77.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $77.545 to $78.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F620% of the shares subject to the stock option vested and became exercisable on the Date of Grant and 20% of the shares vested on each of the 1st 2nd, 3rd and 4th anniversaries of November 12, 2012. The options expire on July 16, 2020.